Page last updated: 2024-12-05

ficusin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ficusin: A naturally occurring furocoumarin, found in PSORALEA. After photoactivation with UV radiation, it binds DNA via single and double-stranded cross-linking. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

psoralen : The simplest member of the class of psoralens that is 7H-furo[3,2-g]chromene having a keto group at position 7. It has been found in plants like Psoralea corylifolia and Ficus salicifolia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
FicusgenusA plant genus of the family MORACEAE. It is the source of the familiar fig fruit and the latex from this tree contains FICAIN.[MeSH]MoraceaeThe mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH]
PsoraleagenusA plant genus of the family FABACEAE that is a source of psoralen (FICUSIN).[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]
Psoralea corylifoliaspecies[no description available]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID6199
CHEMBL ID164660
CHEBI ID27616
SCHEMBL ID17835
MeSH IDM0008462

Synonyms (103)

Synonym
furo[3,2-g]chromen-7-one
ACON1_001579
brn 0152784
7h-furo(3,2-g)(1)benzopyran-7-one
2-propenoic acid, 3-(6-hydroxy-5-benzofuranyl)-, delta-lactone
einecs 200-639-7
furo(4',5',6,7)coumarin
furo(3,2-g)-coumarin
nsc 404562
5-benzofuranacrylic acid, 6-hydroxy-, delta-lactone
hsdb 3528
6-hydroxy-5-benzofuranacrylic acid beta-lactone
c11h6o3
furo(2',3',7,6)coumarin
ccris 4343
tnp00293 ,
NCGC00017351-01
OPREA1_841692
P-7850
inchi=1/c11h6o3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6
7h-furo[3,2-g][1]benzopyran-7-one
furocoumarin
psoralene
furo[2'.3':7.6]coumarin
nsc-404562
psorline-p
nsc404562
furo[4',7]coumarin
6,7-furanocoumarin
furo[4',5':6,7]coumarin
manaderm
furo[2',3':7,6]coumarin
3-(6-hydroxy-5-benzofuranyl)-2-propenoic acid delta-lactone
6-hydroxy-5-benzofuranacrylic acid delta-lactone
CHEBI:27616 ,
66-97-7
C09305
psoralen
7h-furo[3,2-g]chromen-7-one
ficusin
psoralen, >=99% (hplc)
MEGXP0_001172
NCGC00142529-01
MLS001304059
smr000112587
PHYTOALEXIN-CMPD ,
6-hydroxy-5-benzofuranacrylic acid gamma-lactone
BRD-K47264279-001-01-4
psoralene (dcf)
D08450
manaderm (tn)
CHEMBL164660 ,
A835599
7-furo[3,2-g][1]benzopyranone
AKOS004110987
furano[3,2-g]chromen-2-one
bdbm50331544
pyrano[5,6-f]benzofuran-7-one
HMS2267L05
S4737
NCGC00017351-03
NCGC00017351-02
5-19-04-00445 (beilstein handbook reference)
unii-ktz7zcn2ex
ktz7zcn2ex ,
7h-furo[3,2-g]benzopyran-7-one
furo[3,2-g]coumarin
FT-0603268
psoralen [usp-rs]
psoralen [hsdb]
psoralen [mi]
psoralen [who-dd]
6-hydroxy-5-benzofuranacrylic acid .delta.-lactone
SCHEMBL17835
CS-3756
HY-N0053
7h-furo[3,2-g]chromen-7-one #
2-propenoic acid, 3-(6-hydroxy-5-benzofuranyl)-, .delta.-lactone
5-benzofuranacrylic acid, 6-hydroxy-, .delta.-lactone
P2077
DTXSID00216205 ,
mfcd00010520
2h-furo[3,2-g]chromen-2-one
psoralen, analytical standard
AC-7968
psoralen, 97%
AS-59034
furo
furo(4',5':6,7)coumarin
6-hydroxy-5-benzofuranacrylic acid deta-lacton
furo(2',3':7,6)coumarin
psoralen (usp-rs)
7h-furo(3,2-g)chromen-7-one
dtxcid60138696
furo(2',3':7',6)coumarin
7h-furo[3,2-g][1]benzopyran-7-one, 9ci
BCP04177
Q417788
psoralen,(s)
STL564822
CCG-266472
NCGC00017351-07
Z1201617131

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We further conducted a 6-month repeat-dose toxicity study with PAP-1 at 50 mg/kg in both male and female Lewis rats and did not observe any toxic effects."( Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat.
Chen, ZW; Hao, B; Miljanich, GP; Wang, YX; Wulff, H; Zhou, XJ; Zimin, PI, 2011
)
0.37
" using chromatographic techniques and isolation and purification methods, and to observe the transplanted tumor growth inhibitory effects and adverse reactions of psoralen and isopsoralen in nude rats with osteosarcoma."( Isolation and purification of psoralen and isopsoralen and their efficacy and safety in the treatment of osteosarcoma in nude rats.
Liu, D; Lu, H; Song, F; Tang, P; Zhang, L, 2014
)
0.4
" After administration of high doses of psoralen and isopsoralen, toxic reactions such as writhing, lassitude, and hypoactivity were seen."( Isolation and purification of psoralen and isopsoralen and their efficacy and safety in the treatment of osteosarcoma in nude rats.
Liu, D; Lu, H; Song, F; Tang, P; Zhang, L, 2014
)
0.4
"Psoralen and isopsoralen have growth inhibitory effects on transplanted tumor in nude rats with osteosarcoma, and can induce tumor cell apoptosis or necrosis, without significant toxic effects."( Isolation and purification of psoralen and isopsoralen and their efficacy and safety in the treatment of osteosarcoma in nude rats.
Liu, D; Lu, H; Song, F; Tang, P; Zhang, L, 2014
)
0.4
"Fructus Psoraleae (FP) causes cholestatic liver injury; however, its main toxic constituents that are responsible for causing hepatotoxicity remained undetermined in previous studies."( Hepatotoxicity induced by psoralen and isopsoralen from Fructus Psoraleae: Wistar rats are more vulnerable than ICR mice.
Chen, YY; Jiang, JM; Tan, HS; Tang, LM; Wan, SJ; Wang, Y; Xu, HX; Zhang, H; Zheng, D, 2019
)
0.51
" As herbal preparations may interact with pharmaceutical drugs the following in vitro study was undertaken to determine whether the toxic effects of paracetamol on liver cell growth in culture would be exacerbated by the addition of psoralen, a furanocoumarin compound that is present in Psoralea corylifolia, a common Chinese herb."( Paracetamol (acetaminophen) hepatotoxicity increases in the presence of an added herbal compound.
Britza, SM; Byard, RW; Musgrave, IF, 2020
)
0.56
" Psoralen, an active component of Fructus Psoraleae, is toxic to the liver and has various pharmacological properties."( A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity.
Ding, H; Fan, S; Li, X; Li, Y; Liang, C; Sun, S; Wang, M; Wang, S; Yuan, Y, 2022
)
0.72
" Thus, its safe use has attracted increasing attention."( Psoralen induces hepatotoxicity by covalently binding to glutathione-S-transferases and the hepatic cytochrome P450.
Bai, G; Gao, X; Jiang, M; Liu, W; Lu, Y; Lv, B; Ma, X; Wang, X, 2022
)
0.72
"An in vivo experiment was conducted with a time series of 20-80 mg/kg psoralen to verify its toxic performance."( Psoralen induces hepatotoxicity by covalently binding to glutathione-S-transferases and the hepatic cytochrome P450.
Bai, G; Gao, X; Jiang, M; Liu, W; Lu, Y; Lv, B; Ma, X; Wang, X, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
"In this research, pharmacokinetic comparisons of icariin, emodin and psoralen from the extracts of herba Epimedii, Nepal dock root and Ficus hirta yahl, and GKG were conducted."( In vivo pharmacokinetics comparisons of icariin, emodin and psoralen from gan-kang granules and extracts of herba Epimedii, Nepal dock root, Ficus hirta yahl.
Chen, Y; Duan, J; Guo, T; Li, B; Li, Y; Xie, W; Yan, S; Zhou, Y, 2009
)
0.35
"5, 2, 4, 6, 8, 12 and 24 h) after administration, the concentrations of icariin, emodin and psoralen in rat plasma were determined by HPLC-UV, and main pharmacokinetic parameters were estimated."( In vivo pharmacokinetics comparisons of icariin, emodin and psoralen from gan-kang granules and extracts of herba Epimedii, Nepal dock root, Ficus hirta yahl.
Chen, Y; Duan, J; Guo, T; Li, B; Li, Y; Xie, W; Yan, S; Zhou, Y, 2009
)
0.35
"The pharmacokinetic parameters of icariin, emodin and psoralen in GKG were elevated comparing with those of herb extracts."( In vivo pharmacokinetics comparisons of icariin, emodin and psoralen from gan-kang granules and extracts of herba Epimedii, Nepal dock root, Ficus hirta yahl.
Chen, Y; Duan, J; Guo, T; Li, B; Li, Y; Xie, W; Yan, S; Zhou, Y, 2009
)
0.35
" The validated method has been successfully applied to a pharmacokinetic study of psoralen and isopsoralen after oral administration of Haigou Pill to rats."( Simultaneous quantification of psoralen and isopsoralen in rat plasma by ultra-performance liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study after oral administration of Haigou Pill.
Gao, J; Gu, Y; Liu, C; Si, D; Zeng, Y, 2009
)
0.35
" The method was successfully applied to a pharmacokinetic study of eight coumarins in rats after oral administration of radix angelicae pubescentis."( Simultaneous determination of scopoletin, psoralen, bergapten, xanthotoxin, columbianetin acetate, imperatorin, osthole and isoimperatorin in rat plasma by LC-MS/MS for pharmacokinetic studies following oral administration of Radix Angelicae Pubescentis e
Chang, YX; Deng, YR; Gao, XM; Guo, XR; He, J; Li, J; Ma, L; Zhang, BL; Zhang, L; Zhang, P; Zhang, QH, 2013
)
0.39
" The second aim is to investigate the pharmacokinetic properties of PO, IPO, P and IP after oral administration of Psoralea corylifolia extract (PCE) to rats."( A UPLC-MS/MS method for in vivo and in vitro pharmacokinetic studies of psoralenoside, isopsoralenoside, psoralen and isopsoralen from Psoralea corylifolia extract.
Gao, XM; Liu, YN; Qi, AD; Wang, YF; Xiong, W; Xu, YT; Yan, DM; Zhu, Y, 2014
)
0.4
"1% aqueous formic acid was validated according to the criteria in FDA guidelines about bioanalytical method, which was developed to investigate the pharmacokinetic behavior of PO, IPO, P and IP from PCE and the metabolic pathways of PO to P or IPO to IP."( A UPLC-MS/MS method for in vivo and in vitro pharmacokinetic studies of psoralenoside, isopsoralenoside, psoralen and isopsoralen from Psoralea corylifolia extract.
Gao, XM; Liu, YN; Qi, AD; Wang, YF; Xiong, W; Xu, YT; Yan, DM; Zhu, Y, 2014
)
0.4
" After oral administration of PCE to rat, pharmacokinetic parameters of these four compounds indicated that in vivo biotransformation may occur between PO and P or IPO and IP."( A UPLC-MS/MS method for in vivo and in vitro pharmacokinetic studies of psoralenoside, isopsoralenoside, psoralen and isopsoralen from Psoralea corylifolia extract.
Gao, XM; Liu, YN; Qi, AD; Wang, YF; Xiong, W; Xu, YT; Yan, DM; Zhu, Y, 2014
)
0.4
"This paper developed a rapid, sensitive and selective UPLC-MS/MS method for simultaneous determination of PO, IPO, P and IP from PCE in biological samples, and investigated on their comprehensive in vivo and in vitro pharmacokinetic studies."( A UPLC-MS/MS method for in vivo and in vitro pharmacokinetic studies of psoralenoside, isopsoralenoside, psoralen and isopsoralen from Psoralea corylifolia extract.
Gao, XM; Liu, YN; Qi, AD; Wang, YF; Xiong, W; Xu, YT; Yan, DM; Zhu, Y, 2014
)
0.4
" The proliferation rate of osteoblasts was taken as the pharmacodynamic index, and determined by MTT method to draw effect-time curve."( [Analysis on pharmacokinetics-pharmacodynamics correlation of effective ingredients of Qing'e wan].
Chen, ZP; Li, WD; Liu, L; Wang, H; Weng, ZB; Wu, L; Zhu, XY, 2016
)
0.43
" The validated method was successfully applied to the pharmacokinetics (PK) studies of the twenty-one prototypes at pharmacodynamic doses (0."( Simultaneous determination of multiple components in rat plasma and pharmacokinetic studies at a pharmacodynamic dose of Xian-Ling-Gu-Bao capsule by UPLC-MS/MS.
Dai, Y; Dai, ZQ; Gao, MX; Tang, XY; Wu, QC; Xiao, HH; Yao, XS; Yao, ZH; Zeng, JX, 2020
)
0.56
" The developed method was applied to evaluating the pharmacokinetic study of 13 bioactive compounds after oral administration of Psoraleae Fructus in rat of different genders."( Simultaneous characterization of multiple Psoraleae Fructus bioactive compounds in rat plasma by ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry for application in sex-related differences in pharmacokinetics.
Cheng, LY; Song, L; Wu, YL; Yang, L; Yu, YL; Zhang, Y; Zhou, K; Zhou, ZX, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" Two other agents were combined with EB, 3-Carbethoxypsoralene (3 CPs) activated by 365 nm light or gamma rays."( Mitochondrial genetic damage induced in yeast by a photoactivated furocoumarin in combination with ethidium bromide or ultraviolet light.
Hixon, S; Juliani, MH; Moustacchi, E, 1976
)
0.26
"This study aimed to compare the efficacy of targeted microphototherapy alone and in combination with psoralen or calcipotriol in the treatment of plaque-type psoriasis."( Efficacy and safety of non-laser, targeted UVB phototherapy alone and in combination with psoralen gel or calcipotriol ointment in the treatment of localized, chronic, plaque-type psoriasis.
Arca, E; Köse, O; Ozkan, I; Ozmen, I, 2012
)
0.38
"Thirty individuals, affected by plaque-type psoriasis, were treated with targeted narrowband UVB phototherapy alone (Group 1), in combination with psoralen gel (Group 2), or in combination with calcipotriol ointment (Group 3) three times per week based on predetermined minimal erythema doses for 10 weeks."( Efficacy and safety of non-laser, targeted UVB phototherapy alone and in combination with psoralen gel or calcipotriol ointment in the treatment of localized, chronic, plaque-type psoriasis.
Arca, E; Köse, O; Ozkan, I; Ozmen, I, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"The grapefruit juice component bergamottin is known to inactivate cytochrome P450 3A4, with grapefruit juice consumption causing increased absorption and enhanced oral bioavailability of many cytochrome P450 3A4 substrates."( Inhibition of P-glycoprotein transport function by grapefruit juice psoralen.
Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ, 2001
)
0.31
" Inhibition of P-gp by citrus psoralens could present ways both to enhance bioavailability of therapies without increasing the dose and to diminish drug resistance in refractory cells."( Inhibition of P-glycoprotein transport function by grapefruit juice psoralen.
Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ, 2001
)
0.31
" Some ingredients in GKG may increase the dissolution and absorption, and improve bioavailability of icariin, emodin and psoralen in rats."( In vivo pharmacokinetics comparisons of icariin, emodin and psoralen from gan-kang granules and extracts of herba Epimedii, Nepal dock root, Ficus hirta yahl.
Chen, Y; Duan, J; Guo, T; Li, B; Li, Y; Xie, W; Yan, S; Zhou, Y, 2009
)
0.35
"Although the absorption rate constants of psoralen and isopsoralen in duodenum were more than that in jejunum and ileum, there was no significance difference between them."( [Comparative study of absorption kinetics in intestines of rats on Xianlinggubao capsule prepared by different technologies].
Chen, W; Du, S; Li, P; Lu, Y; Ma, Y; Wu, H, 2011
)
0.37
" The absorption rate constants of psoralen and isopsoralen in new Xianlinggubao capsules are higher."( [Comparative study of absorption kinetics in intestines of rats on Xianlinggubao capsule prepared by different technologies].
Chen, W; Du, S; Li, P; Lu, Y; Ma, Y; Wu, H, 2011
)
0.37
" These data show that psoralen is well absorbed and crosses the placental barrier via passive diffusion in the BeWo cell line."( In vitro transport mechanism of psoralen in a human placental cell line (BeWo cells).
Du, W; Guo, J; Han, F; Song, D; Wang, Y; Zhang, W, 2015
)
0.42
" The obtained results showed that salt-processed Buguzhi significantly promoted the absorption of psoralen and isopsoralen, and increased the bioavailability of these compounds."( Evaluation of the influence of salt processing on pharmacokinetics of psoralen and isopsoralen in Psoralea corylifolia L.
Cai, Bc; Chen, Zp; Gao, Qq; He, Jy; Li, Wd; Weng, Zb; Wu, Y; Xu, Zs; Yan, Cp; Zhang, Lj; Zhao, Gh, 2016
)
0.43
" In addition, as candidate drugs, many coumarin compounds have strong pharmacological activity, low toxicity, high bioavailability and better curative effects and have been used to treat various types of diseases."( Psoralen: A Biologically Important Coumarin with Emerging Applications.
Chaudhary, A; Jaswal, VS; Kuca, K; Nepovimova, E; Sharma, R; Thakur, A, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
"Trimethylpsoralen, psoralen and 8-methoxypsoralen were adminstered in 10 mg dosage orally to 37, 29 and 23 patients with vitiligo."( A comparative clinical evaluation of trimethylpsoralen, psoralen and 8-methoxypsoralen in treating vitiligo.
Sehgal, VN, 1975
)
0.25
" In two separate experiments, genistein in a dimethyl sulfoxide/acetone (1:9) solution was applied to SKH-1 female mice 1 h post 8-methoxy-psoralen dosing and 1 h prior to UVA irradiation."( Effects of the isoflavone 4',5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage.
Austin, LM; Lazinsky, A; Lebwohl, M; Lu, Y; Phelps, RG; Saladi, RN; Shyong, EQ; Wei, H, 2002
)
0.31
" Plasma concentrations in RM undergoing a 30-day, chronic dosing study indicated that PAP-1 levels suppressive to TEMs in vitro can be achieved and maintained in vivo at a non-toxic dose."( Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques.
Ansari, AA; Pereira, LE; Raman, G; Sankaranarayanan, A; Villinger, F; Wulff, H, 2007
)
0.34
" However, a dosage of 100 μM suppressed the proliferation of chondrocytes."( Psoralen activates cartilaginous cellular functions of rat chondrocytes in vitro.
Njunge, L; Pan, X; Sun, Y; Xu, K; Xu, W; Yang, L, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
psoralensA furanocoumarin with a 7H-furo[3,2-g]chromen-7-one skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
umbelliferone biosynthesis113
linear furanocoumarin biosynthesis120
scopoletin biosynthesis515
umbelliferone biosynthesis114
linear furanocoumarin biosynthesis221
Linear furanocoumarin biosynthesis015

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
USP1 protein, partialHomo sapiens (human)Potency251.18900.031637.5844354.8130AID743255
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency1.99530.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency3.98110.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency7.94330.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency2.81840.006026.168889.1251AID540317
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency7.94330.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)29.50000.00000.94539.9400AID1624339
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusIC50 (µMol)150.00000.03002.29719.5100AID1803390
Cytochrome P450 2A6Homo sapiens (human)Ki0.60000.00561.52717.5000AID589223
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)IC50 (µMol)3.00000.00011.97318.0000AID539405
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)20.65000.00002.37899.7700AID1624337; AID744458
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)6.48000.00000.933210.0000AID758230
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)60.00000.00001.89149.5700AID1624338
Beta-secretase 1Homo sapiens (human)IC50 (µMol)500.00000.00061.619410.0000AID637774
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (93)

Processvia Protein(s)Taxonomy
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to lipopolysaccharideNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
JNK cascadeNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of gene expressionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of lipid storageNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of vitamin D biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of cholesterol transportNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of interleukin-12 productionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to muscle stretchNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
B cell receptor signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of protein metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mammary gland involutionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription initiation by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to mechanical stimulusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to nicotineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-1Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-6Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to tumor necrosis factorNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to dsRNANuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-17Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to virusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
antibacterial innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of hyaluronan biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to angiotensinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of miRNA metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
proteolysisBeta-secretase 1Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 1Homo sapiens (human)
response to lead ionBeta-secretase 1Homo sapiens (human)
protein processingBeta-secretase 1Homo sapiens (human)
amyloid-beta formationBeta-secretase 1Homo sapiens (human)
amyloid precursor protein catabolic processBeta-secretase 1Homo sapiens (human)
positive regulation of neuron apoptotic processBeta-secretase 1Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painBeta-secretase 1Homo sapiens (human)
prepulse inhibitionBeta-secretase 1Homo sapiens (human)
cellular response to copper ionBeta-secretase 1Homo sapiens (human)
cellular response to manganese ionBeta-secretase 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionBeta-secretase 1Homo sapiens (human)
signaling receptor ligand precursor processingBeta-secretase 1Homo sapiens (human)
cellular response to amyloid-betaBeta-secretase 1Homo sapiens (human)
amyloid fibril formationBeta-secretase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (41)

Processvia Protein(s)Taxonomy
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
transcription cis-regulatory region bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription coregulator activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
identical protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
actinin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
amyloid-beta bindingBeta-secretase 1Homo sapiens (human)
endopeptidase activityBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 1Homo sapiens (human)
protein bindingBeta-secretase 1Homo sapiens (human)
peptidase activityBeta-secretase 1Homo sapiens (human)
beta-aspartyl-peptidase activityBeta-secretase 1Homo sapiens (human)
enzyme bindingBeta-secretase 1Homo sapiens (human)
protein serine/threonine kinase bindingBeta-secretase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (45)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular regionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mitochondrionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytosolNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
secretory granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
specific granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription regulator complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
I-kappaB/NF-kappaB complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
NF-kappaB p50/p65 complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
lysosomeBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
early endosomeBeta-secretase 1Homo sapiens (human)
late endosomeBeta-secretase 1Homo sapiens (human)
multivesicular bodyBeta-secretase 1Homo sapiens (human)
endoplasmic reticulum lumenBeta-secretase 1Homo sapiens (human)
Golgi apparatusBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
synaptic vesicleBeta-secretase 1Homo sapiens (human)
cell surfaceBeta-secretase 1Homo sapiens (human)
endosome membraneBeta-secretase 1Homo sapiens (human)
membraneBeta-secretase 1Homo sapiens (human)
axonBeta-secretase 1Homo sapiens (human)
dendriteBeta-secretase 1Homo sapiens (human)
neuronal cell bodyBeta-secretase 1Homo sapiens (human)
membrane raftBeta-secretase 1Homo sapiens (human)
recycling endosomeBeta-secretase 1Homo sapiens (human)
Golgi-associated vesicle lumenBeta-secretase 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1225511Cytotoxicity against human A549 cells after 48 hrs by MTT assay2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Bioactive Metabolites from the Fruits of Psoralea corylifolia.
AID540201Antibacterial activity against Pseudomonas aeruginosa ATCC 14502 after 18 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID1444506Solubility of the compound in D2O by quantitative nuclear magnetic resonance method2017Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8
Design, synthesis, and biological evaluation of a highly water-soluble psoralen-based photosensitizer.
AID1615747Hepatoprotective activity against H2O2-induced cell death in human HepG2 cells assessed as cell viability at 10 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 24 hrs by EZ-Cytox cell viability assay (Rvb = 43.9 +/- 5.25%)2019Journal of natural products, 09-27, Volume: 82, Issue:9
Furanocoumarins from the Roots of
AID619965Inhibition of NF-KB p50 subunit/DNA interaction after 20 mins by EMSA2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Development of a novel furocoumarin derivative inhibiting NF-κB dependent biological functions: design, synthesis and biological effects.
AID540203Antifungal activity against Saccharomyces sake after 48 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID1444504Photocytotoxicity against mouse BALB/3T3 cells at >42 uM preincubated for 48 hrs followed by 3.3 J/cm2 UV light irradiation for 500 sec measured after 18 hrs by Alamar blue assay2017Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8
Design, synthesis, and biological evaluation of a highly water-soluble psoralen-based photosensitizer.
AID248007Cytotoxicity against HL-60 (human fibrosarcoma) cell line; Range 0.4-16 uM2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Synthesis and photochemotherapeutic activity of thiopyrano[2,3-e]indol-2-ones.
AID1615746Cytotoxicity against human HepG2 cells assessed as cell viability at 10 uM incubated for 1 hr by EZ-Cytox cell viability assay2019Journal of natural products, 09-27, Volume: 82, Issue:9
Furanocoumarins from the Roots of
AID1439494Nematocidal activity against Caenorhabditis elegans2017European journal of medicinal chemistry, Mar-31, Volume: 129Medicinal plants used as anthelmintics: Ethnomedical, pharmacological, and phytochemical studies.
AID467954Antiproliferative activity against mouse EAC cells assessed as ratio of ID50 of compound to ID50 of 8-methoxypsoralen2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Scoring function for DNA-drug docking of anticancer and antiparasitic compounds based on spectral moments of 2D lattice graphs for molecular dynamics trajectories.
AID657025Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Melanogenesis inhibitory bisabolane-type sesquiterpenoids from the roots of Angelica koreana.
AID589179Mechanism based inhibition of human cytochrome P450 2B6, partition ratio (value refers to P450 expressed in lymphoblastoid cells)2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID451810Inhibition of calf thymus DNA topoisomerase 1 assessed as pUC19 DNA relaxation at 10 uM by gel electrophoresis2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Furanocoumarins: novel topoisomerase I inhibitors from Ruta graveolens L.
AID637774Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate after 60 mins by fluorescence quenching assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor.
AID540196Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID1411730Inhibition of recombinant human CYP1A1 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 7-ethoxyresorufin substrate by EROD assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID1624336Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI insect cells using benzylamine as substrate assessed as residual activity at 10 uM after 30 mins by spectrophotometric analysis relative to control2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID451813Inhibition of calf thymus DNA topoisomerase 1 assessed as pUC19 DNA relaxation by gel electrophoresis2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Furanocoumarins: novel topoisomerase I inhibitors from Ruta graveolens L.
AID540205Antifungal activity against Microsporum gypseum after 48 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID1324224Induction of melanin synthesis in mouse B16F10 cells at 50 uM after 48 hrs by spectrophotometric analysis relative to control2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and biological evaluation of furocoumarin derivatives on melanin synthesis in murine B16 cells for the treatment of vitiligo.
AID1225512Cytotoxicity against human K562 cells after 48 hrs by MTT assay2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Bioactive Metabolites from the Fruits of Psoralea corylifolia.
AID1624335Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate assessed as residual activity at 10 uM after 20 mins by spectrophotometric analysis relative to control2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID1624338Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI insect cells using benzylamine as substrate after 30 mins by spectrophotometric analysis2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID1624340Competitive inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by Lineweaver-Burk plot analysis2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID1624339Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by Ellman's method2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID744459Inhibition of mouse brain monoamine oxidase2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
AID540195Antibacterial activity against Helicobacter pylori SS1 assessed as inhibition of visible growth after 96 hrs by agar dilution method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID334650Toxicity in Salmonella Typhimurium T98 at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID489460Antitrypanosomal activity against Trypanosoma brucei brucei at 167 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
7',8'-Dihydroobolactone, a typanocidal alpha-pyrone from the rainforest tree Cryptocarya obovata.
AID540200Antibacterial activity against Shigella flexneri F2a after 18 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID589223Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID400350Inhibition of DNA topoisomerase 2 in human HeLa cells by kinetoplast DNA decantation assay1998Journal of natural products, Mar, Volume: 61, Issue:3
DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia.
AID1225510Inhibition of Streptococcus mutans OMZ65 recombinant sortase A delta-40 mutant using Dabcyl-QALPETGEE-Edans as substrate after 1 hr by fluorescence spectrophotometry2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Bioactive Metabolites from the Fruits of Psoralea corylifolia.
AID540199Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID540204Antifungal activity against Trichophyton rubrum after 48 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID248238Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line; Range 0.4-16 uM2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Synthesis and photochemotherapeutic activity of thiopyrano[2,3-e]indol-2-ones.
AID758230Inhibition of acetylcholinesterase (unknown origin) using acetylcholine iodide as substrate preincubated for 15 mins prior to substrate addition by spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
New bioactive dihydrofuranocoumarins from the roots of the Tunisian Ferula lutea (Poir.) Maire.
AID540202Antifungal activity against Candida albicans ATCC 1600 after 48 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID1439503Antiparasitic activity against Panagrellus redivivus2017European journal of medicinal chemistry, Mar-31, Volume: 129Medicinal plants used as anthelmintics: Ethnomedical, pharmacological, and phytochemical studies.
AID1439504Antiparasitic activity against Bursaphelenchus xylophilus2017European journal of medicinal chemistry, Mar-31, Volume: 129Medicinal plants used as anthelmintics: Ethnomedical, pharmacological, and phytochemical studies.
AID540197Antibacterial activity against Micrococcus luteus ATCC 9341 after 18 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID68590Compound was evaluated for the inhibition of DNA synthesis in Ehrlich Ascites tumor cells by irradiation (365 nm) at 1.9 x 10 e-5M1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Methylangelicins: new potential agents for the photochemotherapy of psoriasis. Structure-activity study on the dark and photochemical interactions with DNA.
AID1615748Inhibition of H2O2-induced ROS accumulation in human HepG2 cells assessed as ROS generation at 10 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 30 mins by H2DCFDA staining based flow cytometry (Rvb = 100 +/- 11.53%)2019Journal of natural products, 09-27, Volume: 82, Issue:9
Furanocoumarins from the Roots of
AID334651Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID540194Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID68591Compound was evaluated for the inhibition of RNA synthesis in Ehrlich Ascites tumor cells by irradiation (365 nm) at 1.9 x 10 e-5M1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Methylangelicins: new potential agents for the photochemotherapy of psoriasis. Structure-activity study on the dark and photochemical interactions with DNA.
AID637775Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate at 500 uM after 60 mins by fluorescence quenching assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor.
AID744458Inhibition of MAO-A (unknown origin)2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
AID758237Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
New bioactive dihydrofuranocoumarins from the roots of the Tunisian Ferula lutea (Poir.) Maire.
AID1225513Increase in SIRT1 (unknown origin) deacetylation activity at 10 uM2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Bioactive Metabolites from the Fruits of Psoralea corylifolia.
AID1624337Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by spectrophotometric analysis2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID539405Inhibition of NF-KB p50 subunit/DNA interaction after 20 mins by EMSA2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Virtual screening against nuclear factor κB (NF-κB) of a focus library: Identification of bioactive furocoumarin derivatives inhibiting NF-κB dependent biological functions involved in cystic fibrosis.
AID1444505Induction of singlet oxygen production in DMSO assessed as decrease in DPBF level by measuring quantum yield after irradiation with halogen light by spectroscopic analysis relative to control2017Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8
Design, synthesis, and biological evaluation of a highly water-soluble psoralen-based photosensitizer.
AID540198Antibacterial activity against Bacillus subtilis CMCC 63501 after 18 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID758234Cytotoxicity against human K562 cells after 96 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
New bioactive dihydrofuranocoumarins from the roots of the Tunisian Ferula lutea (Poir.) Maire.
AID489462Cytotoxicity against HEK239 cells after 72 hrs by Alamar blue assay2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
7',8'-Dihydroobolactone, a typanocidal alpha-pyrone from the rainforest tree Cryptocarya obovata.
AID451811Inhibition of calf thymus DNA topoisomerase 1 assessed as pUC19 DNA relaxation at 20 uM by gel electrophoresis2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Furanocoumarins: novel topoisomerase I inhibitors from Ruta graveolens L.
AID758236Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
New bioactive dihydrofuranocoumarins from the roots of the Tunisian Ferula lutea (Poir.) Maire.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1803390SARS-CoV PLpro Inhibition Assay from Article 10.3109/14756366.2012.753591: \\Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia.\\2014Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 29, Issue:1
Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,005)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990228 (22.69)18.7374
1990's161 (16.02)18.2507
2000's260 (25.87)29.6817
2010's262 (26.07)24.3611
2020's94 (9.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.28 (24.57)
Research Supply Index6.99 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials37 (3.53%)5.53%
Reviews64 (6.10%)6.00%
Case Studies48 (4.58%)4.05%
Observational1 (0.10%)0.25%
Other899 (85.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]